# Keymed Biosciences Co.Ltd clinical trials: 68 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 68 trials with Keymed Biosciences Co.Ltd as lead sponsor, 27 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Keymed Biosciences Co.Ltd: 68 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/keymed-biosciences-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 68
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 68, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07910903 | Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Multiple Myeloma (MM) | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910903) |
| October 28, 2026 | NCT07900945 | Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants | Keymed Biosciences Co.Ltd | Phase 1 | Not yet recruiting | Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900945) |
| October 23, 2026 | NCT07893171 | Study of CM529D1 in Participants With Advanced Solid Tumors | Keymed Biosciences Co.Ltd | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893171) |
| September 16, 2026 | NCT07823764 | Study of CM583 in Healthy Participants | Keymed Biosciences Co.Ltd | Phase 1 | Not yet recruiting | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823764) |
| June 11, 2026 | NCT07642843 | CM336 for Active Sjogren's Syndrome Study | Keymed Biosciences Co.Ltd | Phase 1 | Not yet recruiting | Primary Sjögren's Syndrome (pSS) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642843) |
| April 9, 2026 | NCT07519577 | A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2） | Keymed Biosciences Co.Ltd | Phase 2 | Not yet recruiting | Chronic Rhinosinusitis With Nasal Polyposis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519577) |
| December 18, 2025 | NCT07292688 | Study of CM383 in Healthy Subjects | Keymed Biosciences Co.Ltd | Phase 1 | Recruiting | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292688) |
| November 17, 2025 | NCT07230483 | A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. | Keymed Biosciences Co.Ltd | Phase 2 | Recruiting | Atopic Dermatitis (AD) | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230483) |
| September 18, 2025 | NCT07181239 | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Multiple Myeloma (MM) | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181239) |
| September 16, 2025 | NCT07175506 | Study of CM559 in Healthy Subjects | Keymed Biosciences Co.Ltd | Phase 1 | Recruiting | Healthy Subjects | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175506) |
| September 16, 2025 | NCT07175493 | A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia | Keymed Biosciences Co.Ltd | Phase 1/2 | Recruiting | Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175493) |
| September 10, 2025 | NCT07166211 | Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) | Keymed Biosciences Co.Ltd | Phase 2 | Recruiting | Chronic Spontaneous Urticaria (CSU) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166211) |
| August 6, 2025 | NCT07106372 | A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Atopic Dermatitis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07106372) |
| June 26, 2025 | NCT07039578 | Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis | Keymed Biosciences Co.Ltd | Phase 2 | Recruiting | Primary Light-Chain Amyloidosis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07039578) |
| June 13, 2025 | NCT07019779 | Study of CM518D1 in Patients With Advanced Solid Tumors | Keymed Biosciences Co.Ltd | Phase 1/2 | Recruiting | Advanced Solid Tumors | 434 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07019779) |
| June 8, 2025 | NCT07011524 | Study of CM512 Injection in Subjects With Moderate-to-severe Asthma | Keymed Biosciences Co.Ltd | Phase 2 | Recruiting | Asthma | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011524) |
| May 20, 2025 | NCT06980142 | A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Keymed Biosciences Co.Ltd | Phase 2 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980142) |
| May 4, 2025 | NCT06956196 | Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Atopic Dermatitis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06956196) |
| April 27, 2025 | NCT06947980 | Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis | Keymed Biosciences Co.Ltd | Phase 2 | Recruiting | Atopic Dermatitis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947980) |
| February 17, 2025 | NCT06830395 | Study of CM313 in Subject With IgA Nephropathy | Keymed Biosciences Co.Ltd | Phase 2 | Not yet recruiting | IgA Nephropathy | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06830395) |
| January 24, 2025 | NCT06792019 | Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness | Keymed Biosciences Co.Ltd | Phase 1/2 | Recruiting | Platelet Transfusion Refractoriness | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06792019) |
| January 24, 2025 | NCT06791824 | Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia | Keymed Biosciences Co.Ltd | Phase 1/2 | Not yet recruiting | Aplastic Anemia | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06791824) |
| January 24, 2025 | NCT06791772 | Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) | Keymed Biosciences Co.Ltd | Phase 2 | Not yet recruiting | Systemic Lupus Erythematosus | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06791772) |
| October 1, 2024 | NCT06619613 | A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease | Keymed Biosciences Co.Ltd | Phase 1 | Recruiting | Alzheimer Disease | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06619613) |
| September 19, 2024 | NCT06594146 | Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) | Keymed Biosciences Co.Ltd | Phase 2 | Active not recruiting | Primary Immune Thrombocytopenia | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06594146) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 19 |
| Phase 1/2 | 13 |
| Phase 2 | 26 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 26 |
| Recruiting | 14 |
| Unknown | 13 |
| Not yet recruiting | 13 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dermatitis, Atopic | 15 |
| Multiple Myeloma | 5 |
| Asthma | 4 |
| Rhinitis, Allergic | 3 |
| Alzheimer Disease | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Glomerulonephritis, IGA | 2 |
| Purpura, Thrombocytopenic, Idiopathic | 2 |
| Chronic Urticaria | 1 |
| Disease | 1 |
| Nasal Polyps | 1 |
| Pancreatic Neoplasms | 1 |
| Inflammatory Bowel Diseases | 1 |
| Crohn Disease | 1 |
| Colitis, Ulcerative | 1 |
| Lymphoma | 1 |
| Anemia, Hemolytic, Autoimmune | 1 |
| Evans Syndrome | 1 |
| Anemia, Aplastic | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Rhinitis, Allergic, Seasonal | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Cosmetology schools in the United States](https://specstream.ai/data/businesses/cosmetology-schools/united-states)
- [Jewelry and watches manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-and-watches-manufacturers/united-states)
- [Security system companies in the United States](https://specstream.ai/data/businesses/security-system-companies/united-states)
- [B2B water treatment companies in the United States](https://specstream.ai/data/businesses/b2b-water-treatment-companies/united-states)
- [Flour mills in the United States](https://specstream.ai/data/businesses/flour-mills/united-states)
